Mahmood Ahmad
Tahir Heart Institute
author@example.com

CT.gov Oncology Hiddenness

How much registered oncology evidence still goes quiet on ClinicalTrials.gov once older closed interventional studies are isolated? We analysed 42,344 eligible older oncology studies from the March 29, 2026 full-registry snapshot, making oncology the largest named disease family in the portfolio. The project compares two-year no-results rates, ghost-protocol rates, sponsor-class patterns, phase gradients, and the biggest named sponsors by unresolved stock. Across older oncology studies, 67.0 percent lacked posted results and 42.5 percent showed neither results nor a linked publication. Phase EARLY_ 1 was especially quiet at 87.9 percent on the no-results metric, while National Cancer Institute (NCI) carried the largest sponsor stock at 909 older missing-results studies. Oncology hiddenness is therefore about scale as much as silence, with very large stock spread across public, academic, network, and industry sponsors. That matters for cancer policy, treatment evaluation, and evidence review. These measures describe registry-visible evidence absence rather than adjudicated legal non-compliance within this public oncology frame.

Outside Notes

Type: methods
Primary estimand: 2-year no-results rate within the oncology family among eligible older CT.gov studies
App: CT.gov Oncology Hiddenness dashboard
Data: 42,344 eligible older oncology studies in the March 29, 2026 full-registry snapshot
Code: https://github.com/mahmood726-cyber/ctgov-oncology-hiddenness
Version: 1.0.0
Validation: FULL REGISTRY RUN

References

1. ClinicalTrials.gov API v2. National Library of Medicine. Accessed March 29, 2026.
2. PubMed E-utilities. National Center for Biotechnology Information. Accessed March 29, 2026.
3. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement. BMJ. 2021;372:n71.

AI Disclosure

This work represents a compiler-generated evidence micro-publication built from structured registry data and deterministic summary code. AI was used as a constrained coding and drafting assistant for interface generation, packaging, and prose refinement, not as an autonomous author. The analytical choices, interpretation, and final outputs were reviewed by the author, who takes responsibility for the content.